Year None20222021202020192018201720162015 Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis June 27, 2022 at 4:01 PM EDT Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) June 3, 2022 at 4:30 PM EDT Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update May 12, 2022 at 4:01 PM EDT Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 5, 2022 at 4:30 PM EDT Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis May 3, 2022 at 4:01 PM EDT Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) April 15, 2022 at 4:05 PM EDT Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update March 17, 2022 at 4:01 PM EDT Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference March 2, 2022 at 7:00 AM EST
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis June 27, 2022 at 4:01 PM EDT
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update May 12, 2022 at 4:01 PM EDT
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis May 3, 2022 at 4:01 PM EDT
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update March 17, 2022 at 4:01 PM EDT
Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference March 2, 2022 at 7:00 AM EST